Opens in a new tab

Energy drinks went mainstream before their cardiac safety evidence did

A preliminary analysis of more than 28,000 FDA adverse-event reports found that reports involving caffeinated energy drinks and stimulant supplements disproportionately included cardiac arrest, myocardial infarction, ventricular arrhythmias, palpitations and other cardiovascular events. Nearly half of stimulant-linked cardiovascular reports involved adults aged 18 to 34.

November 12, 2026
Editorial
Energy drinks and pre-workout stimulant products are widely marketed to younger consumers, but serious cardiovascular events appearing in post-market safety reports have renewed calls for stronger surveillance.Pressmaster / Shutterstock.com

IPM Take

Energy drinks occupy an unusually comfortable place in the consumer landscape.

They sit beside soft drinks, appear in gyms and convenience stores, sponsor sport and gaming, and are marketed around alertness, endurance and performance. That familiarity can make them feel closer to flavoured water than pharmacology.

The cardiovascular system does not care how the product is marketed.

Preliminary research from the American Heart Association Scientific Sessions 2026 analysed 28,345 adverse-event reports submitted to an FDA safety database between 2017 and 2025. Reports involving energy drinks or stimulant-containing supplements were substantially more likely than reports involving comparison foods and supplements to mention cardiac arrest, myocardial infarction, ventricular arrhythmia, palpitations, tachycardia, chest pain and syncope.

About 45% of cardiovascular reports involving stimulant products concerned adults aged 18 to 34.

That sounds alarming. It needs equally strong methodological restraint.

The analysis does not tell us that an energy drink makes cardiac arrest 11 times more likely. It does not know how many people consumed the products without an adverse event, reporting is incomplete and highly selective, and the stimulant category combined caffeine with substances including guarana, synephrine, yohimbine and other compounds.

This is pharmacovigilance signal detection, not cardiovascular risk quantification.

But weak evidence of causality is not the same as evidence that surveillance is unnecessary.

The uncomfortable regulatory question is whether products consumed specifically for their physiological stimulant effects should depend so heavily on post-market reports to reveal uncommon cardiovascular harms.

Medicines are expected to establish safety before widespread use.

For many stimulant beverages and supplements, society is effectively learning about safety while millions of people are already consuming them.

That asymmetry is the real signal.

Executive Summary

Preliminary research scheduled for presentation at the American Heart Association Scientific Sessions 2026 examined 28,345 FDA adverse-event reports from 2017 through 2025 involving foods and dietary supplements.

Of those reports, 854 involved caffeinated energy drinks or stimulant-containing dietary supplements, while 27,491 involved products without caffeine or other stimulants.

The stimulant category was broad. It included caffeine, methylxanthine-containing ingredients such as theobromine, guarana, yerba mate and green tea or coffee extracts, as well as sympathomimetic compounds including synephrine, yohimbine, ephedra, DMAA and higenamine.

Compared with reports involving non-stimulant products:

  • cardiac arrest appeared about 11 times more frequently in reports involving caffeine or stimulant products;
  • myocardial infarction appeared about 4.5 times more frequently;
  • ventricular arrhythmias or palpitations appeared about four times more frequently;
  • elevated heart rate appeared nearly three times more frequently;
  • chest pain appeared 2.71 times more frequently; and
  • fainting appeared about twice as frequently.

Approximately 45% of reports connecting stimulant-containing products with cardiovascular events involved adults aged 18 to 34.

These numbers are disproportionality signals within a spontaneous adverse-event database. They are not estimates of absolute cardiovascular risk.

The database does not provide a reliable denominator showing how many people consumed each product, how much they consumed or how many experienced no adverse effects. Reports may also be incomplete, duplicated, selectively submitted or influenced by publicity and other reporting behaviours.

The study additionally grouped products according to stimulant ingredients rather than individual brands, making it impossible to attribute the signal to a particular manufacturer or to caffeine alone.

The research is currently available as a conference abstract rather than a full peer-reviewed publication.

Its findings nevertheless align with the 2026 American Heart Association scientific statement on caffeine and cardiovascular disease, which concludes that moderate caffeinated coffee consumption is generally compatible with cardiovascular health but specifically warns against extrapolating coffee evidence to energy drinks.

Why it matters

  • HTA bodies: This is not a conventional HTA problem, but the evidence illustrates a broader methodological lesson: post-market signals can identify hypotheses that require prospective testing without providing comparative incidence or causal estimates. Any future cardiovascular claims for stimulant products should be evaluated using product-specific exposure, dose and outcome data rather than broad assumptions derived from coffee.
  • Payers: Energy-drink consumption itself is unlikely to become a reimbursed intervention, but preventable emergency presentations, arrhythmia evaluation and cardiovascular work-up create downstream healthcare costs. Clinical pathways for younger patients presenting with unexplained palpitations, chest pain or syncope may benefit from routinely capturing energy-drink and pre-workout stimulant exposure.
  • Industry / innovation partners: Manufacturers have an opportunity to move beyond minimum regulatory compliance through clearer stimulant disclosure, stronger post-market monitoring and product-specific safety research. The products most likely to retain consumer and regulatory trust will be those capable of demonstrating what doses they deliver, how ingredients interact and where clinically meaningful cardiovascular risk begins.

The modern energy drink is one of the more successful exercises in rebranding pharmacology as lifestyle.

Caffeine is consumed for a physiological effect.

People drink it because it changes alertness, wakefulness and performance. Pre-workout supplements are frequently consumed for an even more explicit reason: to alter how the body feels and performs during exercise.

Yet these products are culturally processed very differently from medicines.

They are purchased casually, consumed without clinical supervision and often marketed directly to populations whose baseline cardiovascular risk is assumed to be low.

New preliminary evidence suggests that assumption deserves more scrutiny.

Researchers analysing FDA post-market safety reports found that cardiovascular events appeared disproportionately in reports involving caffeinated energy drinks and stimulant-containing supplements compared with reports involving other foods and supplements.

The dataset included 28,345 adverse-event reports submitted between 2017 and 2025.

Only 854 involved the stimulant-containing products of interest, which immediately establishes one limitation: this is a relatively small subset of a reporting system never designed to estimate disease incidence.

Within those reports, however, cardiovascular outcomes were strikingly overrepresented.

Cardiac arrest was reported around 11 times as frequently.

Myocardial infarction appeared roughly 4.5 times as frequently.

Ventricular arrhythmias and palpitations were approximately four times as common, elevated heart rate nearly three times as common, chest pain 2.71 times as common and syncope around twice as common.

The age distribution makes the findings particularly noteworthy.

About 45% of stimulant-associated cardiovascular reports involved adults aged 18 to 34, an age group in which myocardial infarction and cardiac arrest would ordinarily be substantially less common than among older populations.

That does not mean energy drinks are producing an epidemic of cardiac arrest in healthy 20-year-olds.

The study cannot tell us that.

It does not know how many 18-to-34-year-olds consumed energy drinks during the period without incident. Given the enormous commercial market for these products, that denominator is likely to be vastly larger than the number appearing in an adverse-event database.

Without it, absolute risk cannot be calculated.

There is no legitimate way to turn “11 times more frequently reported” into “11 times greater risk of cardiac arrest”.

That distinction is not statistical pedantry.

It is the difference between a safety signal and a causal estimate.

FDA post-market reporting systems exist precisely because unusual or serious events can emerge after products reach large populations.

But spontaneous reporting is messy by design.

Consumers, clinicians and companies may submit reports. Some events are never reported. Other events may become more likely to be reported after media attention increases. Information about dose, co-exposures and medical history may be incomplete.

And a report that says someone experienced cardiac arrest after consuming a product does not prove the product caused the arrest.

The FDA itself warns against making that inference from adverse-event databases.

Someone could consume an energy drink hours before an arrhythmia caused by an undiagnosed genetic condition. A person taking a pre-workout supplement might also be using nicotine, alcohol, prescription medicines or other stimulants.

Exercise provides another complication.

Many stimulant products are deliberately consumed before intense physical activity, a setting that already changes sympathetic activity, heart rate and blood pressure.

The study therefore identifies a pattern that requires explanation rather than providing the explanation itself.

There is another major source of uncertainty.

“Stimulant” was not synonymous with caffeine.

The analysis included caffeine as well as methylxanthine-containing substances such as guarana, yerba mate, theobromine and tea or coffee extracts. It also included sympathomimetic compounds such as synephrine, yohimbine and several other stimulants.

That makes the findings difficult to translate into a message about ordinary caffeine consumption.

A cup of coffee and a multi-ingredient pre-workout powder are not interchangeable exposures.

The 2026 American Heart Association scientific statement on caffeine makes precisely this point.

The cardiovascular literature on caffeine is dominated by coffee, where caffeine is consumed alongside hundreds of other biologically active compounds and usually within relatively predictable doses.

Moderate coffee consumption has generally not been associated with increased cardiovascular risk and is often associated observationally with lower rates of several cardiometabolic outcomes.

The AHA statement concludes that consuming up to roughly 400 mg of caffeine daily is generally safe for most adults.

That should not become a universal safety threshold for every stimulant product.

Energy drinks can deliver caffeine much more densely than brewed coffee, while pre-workout products can combine caffeine with additional stimulants capable of influencing sympathetic activity and cardiovascular physiology.

How rapidly a dose is consumed may matter too.

Four hundred milligrams of caffeine spread across a day is biologically different from a large bolus consumed shortly before intense exercise.

Individual response also varies considerably.

Caffeine blocks adenosine receptors and increases sympathetic activity, producing temporary effects on blood pressure, heart rate and alertness. Genetics, habitual use, age, medication and underlying disease can modify how strongly a person responds.

For most people consuming ordinary amounts of coffee, those acute effects appear to carry little cardiovascular danger.

At very high stimulant exposure, the risk calculus changes.

The AHA scientific statement notes that high-dose caffeine has been associated with malignant ventricular arrhythmias and that case reports involving energy drinks have raised particular concern about rhythm disturbances.

The new adverse-event analysis adds another layer to that evidence.

It still does not prove causation.

But multiple imperfect evidence streams can justify better surveillance before they justify definitive clinical claims.

That is especially relevant when exposure is widespread.

US sales of energy drinks have grown rapidly, and the products have moved from a niche category into ordinary retail environments.

The cultural signal is one of normality.

A can placed beside water or soda is not perceived like a medicine capable of changing cardiovascular physiology.

A tub of pre-workout powder may be purchased from a supplement store without the consumer ever discussing its stimulant content with a physician or pharmacist.

This is where regulation becomes part of the cardiovascular story.

Dietary supplements in the United States are not subject to the same premarket approval framework as medicines.

Under the Dietary Supplement Health and Education Act, FDA generally does not approve supplements for safety and effectiveness before they reach consumers. Manufacturers bear the initial responsibility for ensuring products meet applicable safety and labelling requirements, while FDA surveillance and enforcement play a substantial role after marketing.

Some energy drinks are marketed as conventional foods rather than supplements, so the exact regulatory pathway differs by product.

Neither pathway turns them into drugs subject to conventional pharmaceutical approval based on prospective clinical trials.

That distinction is important because medicines with direct cardiovascular effects usually face structured premarket clinical evaluation.

Consumer stimulant products generally do not arrive with randomized cardiovascular outcome programmes.

Population exposure therefore grows faster than the clinical evidence base.

The FDA’s post-market reporting infrastructure becomes one of the mechanisms capable of identifying unexpected problems.

That system has value.

The new analysis is evidence of that value.

But it also exposes its limits.

Post-market reports are good at asking: Is something happening here that deserves investigation?

They are poor at answering: How often does it happen, at what dose, in whom and because of which ingredient?

Those are the questions regulators and researchers now need to address.

The 18-to-34-year-old signal is a particularly useful starting point.

Young adults are likely to be major consumers of energy drinks and pre-workout supplements. They may use them around sport, nightlife, shift work, studying and other situations where caffeine exposure can combine with sleep deprivation, dehydration, alcohol, nicotine, recreational drugs or intense exercise.

A serious cardiovascular event in that setting may have multiple contributors.

That does not make the stimulant irrelevant.

It makes exposure characterisation essential.

Future studies should capture product, dose, timing, frequency of consumption, concomitant stimulant use, alcohol or drug exposure, exercise and underlying cardiovascular conditions.

Genetic predisposition may matter too.

Some people experiencing apparently unexplained cardiac arrest or ventricular arrhythmia at a young age ultimately prove to have inherited electrical disorders or cardiomyopathies that were previously silent.

A large stimulant load might conceivably act as a trigger in a susceptible individual without representing the sole cause of disease.

That possibility is clinically different from claiming that an energy drink creates cardiac disease in an otherwise normal heart.

The new data cannot distinguish between the two.

They can influence clinical questioning now.

The investigators specifically argue that clinicians evaluating younger patients with palpitations, chest pain or fainting should ask about energy drinks and stimulant-containing supplements.

That recommendation is pragmatic.

Medication reconciliation is already routine in many clinical settings, but “What medicines do you take?” may not capture a pre-workout powder, energy shot or supplement used before training.

Patients themselves may not consider these products medically relevant.

That information gap becomes particularly important when clinicians are trying to explain tachycardia or palpitations in someone with no obvious structural heart disease.

The clinical response does not need to be panic.

It needs to be exposure awareness.

The same principle should apply to public communication.

Equating all caffeine with cardiovascular danger would contradict a substantial evidence base around moderate coffee consumption.

Equating all energy drinks with cardiac arrest would go far beyond what the new data demonstrate.

But framing these products as physiologically trivial is becoming equally difficult to defend.

The category is too heterogeneous.

An occasional low-caffeine beverage consumed by a healthy adult is not the same exposure as repeated high-dose energy shots or a multi-stimulant supplement used before intense exercise.

Regulation and public-health guidance need enough granularity to make that distinction visible.

That could eventually mean more systematic disclosure of total stimulant exposure, better adverse-event capture and stronger research requirements for high-dose or multi-stimulant products.

The immediate evidence does not establish which regulatory intervention would produce the greatest benefit.

It does establish why relying on aggregate sales and voluntary reports leaves major questions unanswered.

There is also a broader political issue.

Preventive cardiology routinely asks individuals to manage their risks: stop smoking, exercise, improve diet, monitor blood pressure and take medicines when indicated.

Consumer environments simultaneously market products designed to alter physiology while requiring individuals to navigate complex ingredient lists and decide for themselves what constitutes excessive stimulant exposure.

That is a familiar imbalance.

Responsibility is placed downstream, on the consumer, while information about the upstream exposure remains incomplete.

Better regulation would not require treating every can of energy drink as a prescription medicine.

It would require accepting that products marketed for physiological stimulation deserve proportionate safety scrutiny.

The new study cannot tell regulators where that threshold should sit.

Its design is too limited.

The research is also currently a scientific-meeting abstract and has not yet undergone the scrutiny of a full peer-reviewed publication. Details of the statistical methods, reporting definitions, sensitivity analyses and possible confounders therefore remain more limited than they would be in a complete manuscript.

That reduces certainty.

It does not eliminate the signal.

The FDA database itself contains exactly the kind of evidence that should trigger questions rather than answer them.

Those questions now need studies with denominators.

Prospective cohorts could compare cardiovascular outcomes according to quantified stimulant exposure. Controlled physiological studies could evaluate dose effects on blood pressure, repolarisation and arrhythmia susceptibility. Product-specific research could separate caffeine from multi-ingredient stimulant combinations.

And surveillance systems could become better at linking adverse events with actual exposure patterns.

Until then, the most defensible interpretation is deliberately narrow.

The new analysis does not show that energy drinks increase cardiac-arrest risk elevenfold.

It shows that cardiac arrest and several other cardiovascular events appear disproportionately often in reports involving stimulant-containing products.

For a regulator, that is not a verdict.

It is an invitation to investigate.

For clinicians, it is a reason to ask.

And for consumers, it is a reminder that a product does not become physiologically harmless because it is sold next to soda.

Energy drinks have already won the battle to become ordinary consumer products. The evidence challenge now is making sure cardiovascular safety does not remain extraordinary only after something goes wrong.

Source & Evidence